Tumor cells acquire the ability to proliferate uncontrollably, resist apoptosis, sustain angiogenesis and evade immune surveillance. Signal transducer and activator of transcription (STAT) 3 regulates all of these processes in a surprisingly large number of human cancers. Consequently, the STAT3 protein is emerging as an ideal target for cancer therapy. This paper reports the generation of an oncolytic adenovirus (M4), which selectively blocks STAT3 signaling in tumor cells as a novel therapeutic strategy. M4 selectively replicated in tumor cells and expressed high levels of antisense STAT3 complementary DNA during the late phase of the viral infection in a replication-dependent manner. The viral progeny yield of M4 in tumor cells was much higher than that of the parent adenoviral mutants, Ad5/dE1A. M4 effectively silenced STAT3 and its target genes in tumor cells while sparing normal cells and exhibited potent antitumoral efficacy in vitro and in vivo. Systemic administration of M4 significantly inhibited tumor growth in an orthotopic gastric carcinoma mouse model, eliminated abdominal cavity metastases and prolonged survival time. In summary, M4 has low toxicity and great potential as a therapeutic agent for different types of cancers.
Introduction
Signal transducer and activator of transcription (STAT) family proteins are transcription factors activated by many cytokines, growth factors and non-receptor tyrosine kinases (1, 2) . In normal cells, STAT proteins play central roles in cytokine signaling and modulate a variety of biological functions by activating transcription of a diverse set of genes (3) (4) (5) . Activation of STAT proteins is a reversible and tightly controlled process that typically lasts for a limited duration (6, 7) . However, constitutive activation of STAT proteins, especially STAT3, is detected at high frequency in a large number of human malignancies (6, 8, 9) . Persistent activation of the STAT3 protein contributes to multiple malignant phenotypes such as aberrant proliferation, angiogenesis, invasion and immune evasion (10) (11) (12) . Blocking STAT3 signaling has been shown to induce apoptosis in tumor cells, inhibit angiogenesis and enhance antitumor immune-mediated cytotoxicity (10, 13, 14) . Thus, STAT3 has been identified as a potential high-yield target for drug development to treat many cancers (6, 15, 16) . For the past several years, a number of approaches have been employed to block STAT3 signaling pathways. For example, small molecule compounds developed to block STAT3 signaling display potent antitumoral activity (17) (18) (19) . While the safety and therapeutic efficacy of these promising agents is still awaiting evaluation in clinical trials, some fundamental concerns remain to be addressed. Given that STAT3 is a transcription factor ubiquitously expressed in both malignant and normal tissues, the clinical potential of these STAT3 inhibitors would rely on their tumor specificity and lack of toxicity to normal tissues in vivo. Therefore, it is important to develop alternative approaches for selective targeting of STAT3.
Conditionally replicative oncolytic adenoviruses represent a promising new approach in the treatment of cancer (20) (21) (22) , and initial data obtained from clinical studies using oncolytic viruses have been encouraging in terms of efficacy with minimal, if any, toxicity (23) . A number of oncolytic adenoviruses have been engineered by deleting a small sequence in the E1A-or E1B-encoding regions to attenuate viral replication and cytolysis in normal tissues but not in tumor cells. Other attempts to enhance specific tumor cell lysis, including incorporating therapeutic transgenes into conditionally replicative oncolytic adenoviruses, have substantially augmented antitumoral efficacy both in vitro and in vivo (24) . We have previously reported a series of novel oncolytic adenoviral mutants in which we replaced the 6.7K/gp19K region with a fragment of antisense complementary DNA (cDNA) of a target gene in an E1A CR2 region-deleted adenoviral mutant called Adv5/dE1A (25, 26) . The strategy of combining the oncolytic ability with the benefits of gene silencing has proven to be effective and has the potential to be generally applicable in a wide range of molecule-based anticancer therapeutics. This paper reports the generation of a novel adenoviral mutant called M4, which was constructed by replacing E3 adenovirus death protein (ADP) in Adv5/ dE1A with an antisense STAT3 cDNA following Hawkins' gene delivery system (27) . Expression of antisense STAT3 cDNA in M4 mimics the expression kinetics of the native ADP gene and depends strongly on viral DNA replication. M4 showed potent antitumoral efficacy through selective cytolysis and silenced expression of STAT3 and its downstream target genes. Most strikingly, systemic administration of M4 alone significantly suppressed tumor growth in a human orthotopic gastric carcinoma mouse model and eliminated the dissemination in the abdominal cavity.
Materials and methods

Cell culture
Breast cancer (MDA-MB-231), colorectal carcinoma (HCT-8) and lung carcinoma (A549) cell lines were purchased from the American Type Culture Collection (Rockville, MD). A prostate carcinoma (PC3M-1E8) cell line was obtained from the China Center for Type Culture Collection (Shanghai, People's Republic of China). The human gastric cancer cell line (MKN-45) was a gift from Dr Li of the Shanghai Cancer Institute (Shanghai, People's Republic of China). Human umbilical cord endothelial cells (HUVEC) were isolated as described previously (28) . All the cell lines were grown in the recommended medium (GIBCO, Grand Island, NY) supplemented with 10% fetal bovine serum (HyClone, Logan, UT), 2 mmol/L glutamine, 100 U/ml penicillin and 100 lg/ml streptomycin and maintained in a 37°C atmosphere containing 5% CO 2 .
Adenoviral mutants
Ad5/dE1A with deletion of amino acids 121-129 in E1A CR2 was previously constructed (25) . M4 was driven from Ad5/dE1A through replacement of the ADP open reading frame in the E3 region by a fragment of reverse STAT3 cDNA (bases 960-190). Ad5/dE1A/ADP was driven from Ad5/dE1A through deletion of the ADP open reading frame and used as a vector control for M4. The viral mutants were constructed by homologous recombination in the human embryonic kidney 293 (HEK-293) cells.
Detection of antisense STAT3 cDNA and gp19K/STAT3 cDNA fusion messenger RNA A549 cells were infected with virus at an multiplicity of infection (MOI) of 10, cultured for various times and collected for extraction of total RNA. A sense primer (5#-GCTCACTCACGATGCTTCTC-3#) and an antisense primer (5#-ATTGACCAGCAGTATAGCCG-3#) were used for amplification of antisense STAT3 cDNA. For amplification of the fusion transcript containing sequences of gp19K gene and antisense STAT3 cDNA, a 5#-end sense primer from the coding region of gp19K (5#-GGTGGTTCTCCATAGCGCTT-3#) and a 3#-end antisense primer complimentary to the antisense STAT3 cDNA (5#-TACA-GACTGCAGCCACTGCG-3#) were used.
TCID 50 to determine viral titers for burst assay A549 cells were infected with different viruses at an MOI of 20. The viral yield was determined by the limiting dilution method, known as the determination of 50% tissue culture infective dose (TCID 50 ) described elsewhere (27) . The data from three separate infection studies were expressed as plaque-forming unit per milliliter and normalized to virus production per cell based on the number of infected cells.
Real-time polymerase chain reaction
The cells were infected with various viral mutants at an MOI of 10. At various time points post-infection (p.i.), total RNA was isolated from the cells and treated with DNase I for 30 min at 37°C. Real-time PCR (RT-PCR) was performed using the SYBR Premix Ex Taq Kit (TaKaRa Biotechnology Co., Ltd, Dalian, China). All fold differences in expression were normalized relative to 18s RNA expression in the corresponding sample. Primers used for RT-PCR are as follows: gp19K-forward (F): 5#-TTTAAGGAGCCAGCCTGTAATGT-3#, reverse (R): 5#-GCAGCTTTTCATGTTCTGTGGT-3#; receptor internalization and degradation (RID)-b-F: 5#-GCAATCATCTCTGTTATGGTGTTCT-3#, R: 5#-GGGGAAAGTTGGGTGGTTC-3#; 14.7K-F: 5#-AGGCCAAAGT-CACCTACGACA-3#, R: 5#-TCCCACCATGACCACCAA-3#; STAT3-F: 5#-CCAGTCAGTGACCAGGCAGAAG-3#, R: 5#-GCACGTACTCCATCGCT-GACA-3#; survivin-F: 5#-AGGTCATCTCGGCTGTTCCTG-3#, R: 5#-TCATCCTCACTGCGGCTGTC-3#; and STAT5a-F: 5#-AGGACTA-CAGTGGCCTGTCC-3#, R: 5#-GTGCTTCTTCAACACCTCCA-3#. 
Western blot analysis
Apoptosis assay
Fluorescein isothiocyanate-annexin V and propidium iodide staining (BD Biosciences Pharmingen, San Diego, CA) were used to determine apoptosis according to our previously described methods (25) .
Matrigel invasion assay
Twenty-four hours p.i., MDA-MB-231 or HCT-8 cells infected with the indicated viruses at an MOI of 10 were trypsinized and counted, and 2 Â 10 5 cells were placed in matrigel-coated transwell inserts (8 lm pores). Cells were allowed to invade through the matrigel for 22 h. Then, cells in the upper chamber were removed by using cotton swabs. Cells adhered to the outer surface that had invaded through the matrigel were fixed and stained with crystal violet solution (Sigma Chemical Co., St Louis, MO). Cells were counted at a magnification of Â400 in 10 randomly selected fields, and the mean number of cells per field was recorded.
In vitro angiogenesis evaluation In vitro formation of tubular structures was studied on extracellular matrix as described below. Briefly, 24-well plates were coated with cold matrigel (80 ll per well of a solution of 9:1 EC Matrigel to 10Â buffer). Then, 1 Â 10 5 HUVEC cells suspended in the conditioned media collected from cell cultures of PC3M-1E8 or MKN-45 cells infected with 10 MOI of various viral mutants were seeded in each well. After 16 h incubation, angiogenesis was assessed based on formation of capillary-like structures. The number of capillary-like tubes was counted in five randomly chosen microscopic fields (Nikon Eclipse, TE2000-U), and the average was calculated.
Small interfering RNA preparation Small interfering RNA (siRNA) against human STAT3 (5#-GGAGCAGCACCUU-CAGGAUTT-3#) was synthesized according to the published sequence (29) , and non-targeting control siRNA (5#-UACCGACUAAAGACAUCAAUU-3#) was high-performance liquid chromatography purified. RNA oligonucleotides were ordered from Invitrogen (Shanghai, People's Republic of China).
Mouse tumor models
Athymic BALB/c nude mice were purchased from the Animal Experimental Center of Slaccas (Shanghai, People's Republic of China). The 4-to 6-weekold mice were maintained in laminar flow cabinets under specific pathogenfree conditions. In the direct intratumoral (i.t.) injection studies, 3 Â 10 6 PC3M-1E8 cells or 1 Â 10 6 MKN-45 cells were suspended in 100 ll normal saline, injected subcutaneously in the right flanks of mice and allowed to develop into a tumor of 4-6 mm in diameter before treatment. Then, 1 Â 10 8 pfu doses of each virus were injected directly into tumors once daily for five consecutive days (n 5 5 for each group). Tumors were measured in two dimensions with calipers twice weekly, and the volume was calculated as length Â width 2 Â 0.52. The mice were killed when the tumor volume was .800 mm 3 for PC3M-1E8 and 1800 mm 3 for MKN-45. A parallel experiment was performed to determine STAT3 and its target protein levels (n 5 2 for each group). For siRNA injection, 6 lg of siRNA with polyethylenimine complexes were injected into tumors once daily for five consecutive days (n 5 3 for each group). Tumors were harvested from mice 3 or 15 days after injection and analyzed for STAT3 expression. The orthotopic gastric cancer mouse model was established as described previously (30) . Ten days after orthotopic implantation, mice were randomly assigned into four groups (n 5 15 each group), and 2 Â 10 8 pfu of virus was injected into the tail vein daily for five consecutive days. Five mice were selected randomly from each group to examine tumor growth and metastases and were then killed on day 42 after implantation. Ten mice were monitored for death and were euthanized when they appeared moribund. A parallel experiment was performed to determine in vivo viral replication or endogenous STAT3 protein levels (n 5 2 for each group).
Immunohistochemistry and in situ hybridization
Immunohistochemical labeling of tissues and in situ hybridization staining were performed as described previously (30) .
Statistical analysis
Statistical values are presented as mean ± SEM. The significance of differences between groups was assessed by the two-tailed Student's t-test. Statistical significance was defined as P ,0.05. Survival was analyzed by the KaplanMeier method and differences were analyzed by a log-rank test.
Results
Construction and confirmation of M4
Two artificial features were combined into one wild-type adenovirus 5 (wt-Ad5) genome to generate the M4 mutant adenovirus ( Figure 1A ). First, a 27 bp sequence from wt-Ad5 bases 920-946 was deleted to generate Ad5/dE1A, which expresses a mutant E1A protein lacking the CR2 domain necessary for pRb binding. Second, the E3 transcription unit of the Ad5/dE1A genome, corresponding to wt-Ad5 bases 29 477-29 714 known to encode the ADP protein, was selectively excised and substituted by a fragment of reverse STAT3 cDNA (bases 960-190) to generate M4. In M4, antisense STAT3 cDNA was fused to the 3# portion of the E3 gp19K gene to yield a single chimeric transcript. Expression of the chimeric transcript was detected in A549 cells infected with M4 ( Figure 1B) . The genomic structure of M4 was further verified by restriction digest with ClaI, and the appearance of a 0.77 kb-long band confirmed the insertion of STAT3 cDNA and deletion in the E1A region ( Figure 1C ).
Antisense STAT3 cDNA expression from M4 mimicks the ADP expression pattern To test whether the expression pattern of reverse STAT3 cDNA in M4 mimicked that of the native ADP gene, A549 cells were infected with M4 or wt-Ad5. The expression pattern of the antisense STAT3 transgene was determined and compared with that of the native ADP gene over the course of the viral infections. The transcriptional expression of antisense STAT3 cDNA in M4 was nearly undetectable 12 h p.i. but was at a high level 36 h after infection, similar to the expression pattern of ADP (Figure 2A ). In wt-Ad5, native ADP expression is highly dependent on viral replication. To address whether reverse STAT3 cDNA expression from M4 retained this feature, its expression was analyzed in the presence or absence of Ara-C, a viral DNA replication inhibitor. To validate the experimental conditions, the native adenoviral genes pVIII and gp19K were included as positive and
Oncolytic adenovirus silences the expression of STAT3 negative controls, respectively. pVIII is a structural gene from the adenoviral late transcription unit L4, and its expression is completely dependent on viral DNA replication. In contrast, gp19K is a viral early response gene whose transcription is much less dependent on DNA replication. In the absence of Ara-C, transcripts of pVIII, gp19K or the antisense STAT3 were readily detected in A549 cells infected with M4, and these genes were expressed at levels similar to those obtained with wt-Ad5 infection ( Figure 2B ). In the presence of Ara-C, the transcription of pVIII and ADP was almost completely abolished, whereas the expression of gp19K was not significantly changed. As expected, the expression of antisense STAT3 cDNA from M4 mimicked the pattern of the native ADP gene and was almost completely inhibited by the addition of Ara-C ( Figure 2B ). Next, we tested whether the transgene in M4 could be expressed in replication-non-permissive cells. HUVECs were infected with wt-Ad5 or M4 and examined for transcript levels of ADP or antisense STAT3. While the transcripts of gp19K and ADP were easily detected in wtAd5-infected HUVECs, only gp19K transcripts were detected in M4-infected HUVECs, and antisense STAT3 cDNA transcripts were nearly undetectable ( Figure 2C ).
Expression of genes adjacent to the site of ADP transgene insertion is maintained in M4
In wt-Ad5, the expression timing and levels of E3 genes are controlled by a number of cis signals. One of these signals is encoded within the ADP gene (31) . To address whether the artificial modification in M4 altered the expression of E3 genes adjacent to the ADP gene, A549 cells were infected with various viral mutants and the expression of the E3 genes gp19K, RIDb and 14.7 K, which surround the ADP gene, was examined by RT-PCR. Although there was a minor difference at different times p.i., the expression timing and levels of the gp19K, RIDb and 14.7 K genes in Ad5/dE1A/ADP and M4 infection were similar to those seen in the wt-Ad5 infection ( Figure 2D ). 
M4 specifically depletes the STAT3 protein and its downstream target genes in cancerous but not in normal cells
To assess the efficacy of M4 in downregulating endogenous STAT3 protein in cancer cells, PC3M-1E8 and MKN-45 cells were infected with M4 at an MOI of 10. Immunoblot analysis of whole-cell lysates showed significant reduction in expression of STAT3, p-STAT3 and its target proteins ( Figure 3A and B) in a time-dependent manner. In contrast, infection of normal cells (HUVEC) with M4 at an MOI of 100 did not change the STAT3 protein levels ( Figure 3C ). These results demonstrate the selectivity of M4 to inhibit STAT3 expression in cancer cells. In order to rule out the possibility that the reduction in these proteins was the result of their degradation during apoptosis and had nothing to do with specific downregulation of these genes by M4, we examined the level of another endogenous protein, STAT5a. The results show that the level of STAT5a protein was not affected in M4-infected cells ( Figure 3D ). Moreover, c-myc and survivin, which are short-lived proteins, were not reduced by Ad5/dE1A or Ad5/dE1A/ADP even at 96 h p.i. (Figure 3A and B) . For M4 to reduce STAT3 target proteins, translation of STAT3 messenger RNA (mRNA) must be inhibited thereby reducing the transcription of STAT3 target genes. We next determined the transcriptional level of STAT3, survivin and STAT5a in M4-infected cells by RT-PCR. The results show that significant downregulation of STAT3 mRNA levels was observed in the M4-infected cells and the decrease of survivin mRNA levels corresponded to the downregulation of STAT3, but the STAT5a mRNA levels were not significantly changed ( Figure 3E ). The data above show the specificity of M4 to selectively inhibit STAT3 and its target proteins in cancer cells.
Cytolytic potency of M4 and viral yield
In wt-Ad5, the ADP gene promotes the death of infected cells and participates in the release of the virus (32) . To address how the substitution of antisense STAT3 cDNA for the ADP gene altered cytolytic potency, Ad5/dE1A, Ad5/dE1A/ADP and M4 were analyzed for the ability to induce a cytopathic effect (CPE) in A549 cells. While nearly all Ad5/dE1A-infected cells rounded up and detached by 72 h p.i., many of the cells infected with Ad5/dE1A/ADP remained attached and intact ( Figure 4A ). CPE was delayed in cells infected with M4 compared with Ad5/dE1A but was earlier than those infected with Ad5/dE1A/ADP ( Figure 4A ). In primary normal HUVECs, wt-Ad5 caused complete CPE by 12 d p.i. at an MOI of 0.1. In contrast, M4, Ad5/dE1A and Ad5/dE1A/ADP exhibited no detectable CPE in HUVECs at an MOI of 100 ( Figure 4B ). To address whether the weakened CPE gave rise to a higher yield of progeny virions, A549 cells were infected with Ad5/dE1A, Ad5/dE1A/ADP or M4, and then, Fig. 3 . Expression of STAT3 and downstream genes in cancer cells and normal primary cells infected with M4. PC-3M-1E8, MKN-45 or HUVEC cells were infected with various viral mutants at an MOI of 10 and cultured for the designated time. Protein or mRNA was then extracted and subjected to western blot or real-time PCR analysis, respectively. Western blot analysis showed that STAT3 and its downstream targets were downregulated in both cancer cell lines infected with M4 but not those infected with Ad5/dE1A or Ad5/dE1A/ADP (A and B). In contrast, M4 had no effect on STAT3 expression in HUVECs (C). On the other hand, M4 did not affect the levels of other endogenous proteins, such as STAT5a and b-actin (D). RT-PCR analysis showed that a significant downregulation of STAT3 and survivin mRNA levels in the M4-infected cancer cells, but the mRNA levels of STAT5a were not changed significantly. The mRNA expression of the genes in both kinds of cells at 0 h p.i. was set as 1 (E).
Oncolytic adenovirus silences the expression of STAT3
the cells and culture medium were harvested separately at various time points p.i. and assayed for the production of infectious virus. The level of Ad5/dE1A virions in harvested A549 cells increased robustly at 48 h p.i. and began to decline after this time point. Meanwhile, the level Ad5/dE1A virions in the culture supernatant displayed a continuous increase ( Figure 4C ). The level of Ad5/ dE1A/ADP virions in A549 cells was still increasing at 72 h p.i. and did not decline significantly until 120 h p.i. At the same time, there was a lower level of release of Ad5/dE1A/ADP virions into the culture supernatant ( Figure 4C ). Interestingly, although cellular M4 levels in A549 cells continued to increase even at 72 h p.i., they began to decline sharply thereafter along with a rapid release of virions into the culture medium ( Figure 4C ). Therefore, M4 can produce larger viral progeny yield than Ad5/dE1A, lyse cancer cells more efficiently than Ad5/dE1A/ADP and spread better in tumors than either Ad5/dE1A or Ad5/dE1A/ADP.
M4 shows potent antitumoral efficacy, prevents tumor cell invasion and inhibits angiogenesis in vitro
Because M4 can specifically deplete STAT3 protein and its downstream target genes and produce large viral progeny yield in cancer cells, we next evaluated the therapeutic benefits of M4. A panel of cancer cells with different tissue origins and STAT3 status were selected for the study. As shown in Figure 5A , the apoptosis rate of cancer cells was markedly higher in M4 than in Ad5/dE1A-or Ad5/ dE1A/ADP-treated cells. In these experiments, both M4 and its parental viruses express E1B-19K, which is a functional analog of Bcl-2 that inhibits apoptosis ( Figure 5B ). However, adenoviruses may also encode a number of proteins that function as inducers of apoptosis at later stages of infection (33) . Therefore, Ad5/dE1A-or Ad5/dE1A/ ADP-induced apoptosis of cancer cells is brought about by the cytolytic potency of the oncolytic adenoviruses. The enhanced cytotoxicity of M4 to cancer cells should be due to the incorporation of antisense STAT3 cDNA. The invasive potential of HCT-8 and MDA-MB-231 cells infected with M4 was assessed at 48 h p.i. Both cancer cell lines showed a lasting reduction of endogenous levels of STAT3 when infected with M4 but only a minor apoptosis response at that time ( Figure 5A ). To further examine the functional relevance of decreased expression of STAT3 downstream target genes, we evaluated the effects of M4 on MMP-9 expression and invasive potential in HCT-8 and MDA-MB-231 cells. Consistent with the reduction in STAT3 and MMP-9 expression, M4-infected HCT-8 and MDA-MB-231 cells displayed at least a 2-fold decrease in invasive potential as compared with that of Ad5/dE1A-or Ad5/dE1A/ADP-infected cells ( Figure 5C ), and overexpression of MMP-9 in cancer cells infected with M4 partially rescued the invasive potential ( Figure S1 ). Next, we examined whether the angiogenesis-inducing ability of the conditioned medium from M4-infected tumor cells was suppressed. As expected, the pro-angiogenic potency of M4-infected tumor cells was significantly inhibited (Figure 5D ).
M4 suppresses tumor growth and eradicated metastasis in vivo
The in vivo antitumoral efficacy of M4 was examined in two ectopic xenograft models and one orthotopic xenograft model. Ectopic xenograft models were first employed to test the therapeutic efficacy of i.t. injection of M4. Compared with control (Ad5/dE1A-or Ad5/ dE1A/ADP-treated) tumors, those in mice that received M4 displayed strong growth inhibition ( Figure 6A ). Control animals developed symptoms like anorexia and weight loss before they were killed, whereas M4-treated animals remained symptom free. Confirming the in vitro findings, western blotting of tumor lysates also revealed a significant reduction in STAT3 protein levels and STAT3 downstream target genes even 30 days after i.t. injection, and the effect of downregulation was still obvious (Figure 6B and C) . In contrast, STAT3 siRNA produced a transitory downregulation of STAT3 protein by direct i.t. injection ( Figure 6C ). In the orthotopic xenograft model, primary tumor volume, local invasion and abdominal cavity metastasis were all significantly decreased in the animals treated with M4 compared with Ad5/dE1A or Ad5/dE1A/ADP (Table 1) , and M4 treatment significantly extended the survival timeof tumor-bearing mice (P , 0.01, Figure 6D ). At 30 day after the last systemic administration of M4, efficient viral replication was found in the viable tumor tissue and a significant number of necrotic tumor cells was seen in adjacent tissue ( Figure 6E) . Depletion of Oncolytic adenovirus silences the expression of STAT3 tumor-associated STAT3 protein was seen in mice treated by intravenous injection of M4 but not Ad5/dE1A, Ad5/dE1A/ADP or phosphate-buffered saline ( Figure 6F ). To assess the adverse effects of the treatment, the levels of alanine aminotransferase and aspartame aminotransferase in serum of mice were assayed. Compared with the mice injected with phosphate-buffered saline, mice injected with M4 also showed a slight increase in the levels of aspartame aminotransferase and alanine aminotransferase; however, the increase was much lower than those caused by wt-Ad5 (supplementary Figure S2 is available at Carcinogenesis Online). 
Discussion
Although numerous lines of evidence have validated STAT3 as a promising target for cancer therapy, the development of agents that inhibit STAT3 with sufficient potency and good tumor selectivity has proven to be a formidable task. For example, one of most promising approaches to targeting STAT3 is to inhibit phosphorylation of STAT3 using small molecule compounds. However, some studies have demonstrated that unphosphorylated STAT3 is also important for oncogenesis (34, 35) . The main contribution of the current study is the development of M4 for selective depletion of STAT3 protein in tumor cells but not in normal cells. By combining the oncolytic properties of Ad5 with the benefits of targeting the STAT3 protein by antisense RNA, M4 demonstrated potent antitumoral efficacy and even more attractively great potential to control metastases. Three bioengineered features are responsible for the potency and selectivity of M4. First, M4 contains a 27 bp deletion in the E1A CR2 necessary for pRb binding. This modification enables M4 to replicate efficiently in and lyse cells with a defective G 1 -S checkpoint, which is seen in almost all tumor cells as a result of a loss of function of in the Rb pathway. Second, the current design employed the ADP region for insertion of the therapeutic transgene, which lies directly downstream of the gp19K gene in the E3 transcription unit and has the same polyadenylation site as the gp19K gene. Unlike gp19K, which begins to be greatly amplified in early stage of viral infection, expression of ADP is driven mainly by the adenovirus major late promoter and only operates at a high level during the late phase of the viral infection in a replication-dependent manner (27) . Our data demonstrate that M4 generated by this strategy allowed for a latent cytolysis, favoring higher viral production without undermining the final oncolytic potency. Third, placing reverse STAT3 cDNA into the deleted ADP locus in M4 enabled the highly selective expression of transcripts of antisense STAT3 in tumor but not normal cells and subsequently depletion of tumor cell STAT3 levels.
It is true that the oncolytic adenovirus-infected tumor cell should die from oncolysis anyway. However, complete oncolysis only occurs in in vitro cell culture models. On the other hand, many obstacles in vivo exist to limit the abilities of oncolytic adenoviruses, which is clearly exemplified by clinical trials with oncolytic adenovirus (36) . Therefore, many investigators (including our group) have successfully developed a variety of oncolytic adenoviral mutants by incorporating different transgenes, such as antisense plk1 or chk1 cDNA (25, 26) . Because STAT3 is a direct transcriptional activator of a large number of downstream genes, targeting STAT3 appears to have more theoretically advantageous and is unique. In addition to the high frequency of constitutive activation of STAT3 in tumors, STAT3 activation has additive effects for maintaining multiple malignant behaviors such as proliferation, angiogenesis and immune evasion (6) . Oncolytic adenoviral mutants armed with antisense plk1 or chk1 cDNA are unlikely to produce bystander effects, which could limit the potency of tumor eradication. On the other hand, silencing of STAT3 has been reported to elicit potent bystander effects, which might be caused by mechanisms such as reactivation of antitumor immunity, inhibition of angiogenesis and reduction of the release of soluble cytokines (6) . Most recently, compelling evidence has shown that inhibiting STAT3 signaling elicits multicomponent antitumor immunity and reverses immune tolerance (10) . Our study showed that when armed with antisense STAT3 cDNA, M4 significantly enhanced its ability to induce apoptosis and inhibit invasive potential and angiogenesis of cancer cells compared with Ad5/dE1A or Ad5/dE1A/ADP. One of the most interesting findings was that the human metastatic gastric tumor mouse model responded to systemic administration of M4 with a substantially reduced incidence of metastases. The unexpected elimination of metastatic progression by M4 is of great significance and is an advance from the failure of M1 as a single agent to reduce the frequency of metastatic progression in our previous publication (26) . The anti-metastatic potential of M4 could in part be due to the inhibition of angiogenesis and loss of invasiveness, which are controlled by STAT3.
Concerns exist about the clinical potential of oncolytic adenoviral mutants, including M4. Up to now, the major route of administration of adenovirus therapy in clinical use has been direct i.t. injection. For this reason, adenovirus gene therapy is now generally regarded as an adjuvant approach for local tumor control, which severely limits the potential of oncolytic adenoviruses in vivo. However, we recently showed that systemic administration of oncolytic adenovirus M1 allows it to effectively spread and replicate in local and distant metastases (30) . The current study provides further evidence that systemic administration of oncolytic adenovirus M4 could prevent the metastatic progression of primary tumors by selectively silencing tumorassociated STAT3. Whether the present findings can be translated into clinical benefits remains to be determined in future clinical trials. Because the STAT3 protein is difficult to target, the current approach is an attractive potential treatment strategy. The findings presented here are encouraging enough to warrant further laboratory and clinical evaluation. 
